Abstract:Two decades ago, it seemed almost inconceivable that China would be heading towards an epidemic of obesity and type 2 diabetes; HIV/AIDS and other communicable diseases were much greater concerns. Rapid economic growth and investment in health systems have led to growing income, rapidly declining infectious disease rates, and increasing life expectancy.1Yang G Wang Y Zeng Y et al.Rapid health transition in China, 1990–2010: findings from the Global Burden of Disease Study 2010.Lancet. 2013; 381: 1987-2015Summary Full Text Full Text PDF PubMed Scopus (1499) Google Scholar This good news story, however, carries with it the baggage of an increasing burden of obesity and diabetes. In 1994, it was estimated that the prevalence of diabetes was 2·5%.2Pan XR Yang WY Li GW Liu J Prevalence of diabetes and its risk factors in China, 1994.Diabetes Care. 1997; 20: 1664-1669Crossref PubMed Scopus (452) Google Scholar Estimates for 2014 suggest that this prevalence has now risen to between 9·7% and 11·6%3Ma RCW Lin X Jia W Causes of type 2 diabetes in China.Lancet Diabetes Endocrinol. 2014; 2: 980-991Summary Full Text Full Text PDF Scopus (112) Google Scholar and there is no indication that rates are going to decline soon. Like many countries undergoing a similar demographic and economic transition, China has been slow to respond to the associated change in disease burden. The focus of the Millennium Development Goals on maternal, neonatal, and child health and infectious diseases has left non-communicable diseases (NCDs) to grow relatively unnoticed—or worse, completely ignored—in the shadows. However, there are signs that China is beginning to recognise and react to the challenge that NCDs, and especially diabetes and obesity, pose.4Jia W Tong N Diabetes prevention and continuing health-care reform in China.Lancet Diabetes Endocrinol. 2015; 3: 840-842Summary Full Text Full Text PDF Scopus (15) Google Scholar In particular, the health system is beginning to adapt and embrace hierarchical systems of care, which might be better suited to managing high volumes of patients with chronic diseases and their associated sequelae.4Jia W Tong N Diabetes prevention and continuing health-care reform in China.Lancet Diabetes Endocrinol. 2015; 3: 840-842Summary Full Text Full Text PDF Scopus (15) Google Scholar However, treatment and prevention efforts cannot be imported wholesale to China from health systems elsewhere. Patients in China are culturally, as well as physiologically, different from patients in many other countries.3Ma RCW Lin X Jia W Causes of type 2 diabetes in China.Lancet Diabetes Endocrinol. 2014; 2: 980-991Summary Full Text Full Text PDF Scopus (112) Google Scholar Importantly, Chinese people get diabetes at a much lower BMI than their European counterparts, and β-cell dysfunction, rather than insulin resistance, is likely to be the primary defect leading to hyperglycaemia.3Ma RCW Lin X Jia W Causes of type 2 diabetes in China.Lancet Diabetes Endocrinol. 2014; 2: 980-991Summary Full Text Full Text PDF Scopus (112) Google Scholar These key physiological differences necessitate treatment regimens and guidelines for starting treatment that are tailored to the Chinese population.5Yang W Weng J Early therapy for type 2 diabetes in China.Lancet Diabetes Endocrinol. 2014; 2: 992-1002Summary Full Text Full Text PDF Scopus (24) Google Scholar Prevention strategies also need to take into account the dietary, cultural, and societal needs of the population.6Chan JCN Zhang Y Ning G Diabetes in China: a societal solution for personal challenge.Lancet Diabetes Endocrinol. 2014; 2: 969-979Summary Full Text Full Text PDF Scopus (159) Google Scholar Ensuring that diabetes solutions are tailored to the population in China will depend on concerted research efforts in all domains, but especially in the areas of health systems development, data management, epidemiology, and diabetes prevention and treatment. Research in China is already rising to the challenges ahead and Lancet journals are proud to partner with our colleagues in China in this endeavour. For the Chinese Diabetes Society meeting in 2016, the Chinese Diabetes Society, The Lancet Diabetes & Endocrinology and The Lancet will host a session for researchers to present their findings relating to diabetes and obesity in China. Submissions that are judged to be of high enough quality will be presented either orally or as posters, with abstracts being published in The Lancet Diabetes & Endocrinology. Additionally, for studies judged to be of highest quality there is potential for publication as a full Article in one of the journals. In the first instance, we ask you to submit your best quality, clinically relevant research as structured abstracts to The Lancet Diabetes & Endocrinology by June 31, 2016. Abstracts should be a maximum of 500 words in length and contain no references, tables, or figures. Submissions should be written in English and include the following sections: title; names and affiliations of authors; address and email address for the corresponding author; background, including context and aim; methods; findings; interpretation; and funding. Statements about the contributions made by each co-author and a declaration of competing interests should also be included. A team of independent experts will select the abstracts to be presented at the session. We will also contact the authors of any abstracts that are deemed suitable for consideration for publication as a full Article in either The Lancet Diabetes & Endocrinology or The Lancet. We look forward to seeing your submissions. WJ declares no competing interests.

Standards of Care for Type 2 Diabetes in China

Standards of medical care for type 2 diabetes in China 2019

Changing Epidemiology of Metabolic Syndrome and Type 2 Diabetes in Chinese Youth

Pediatric Diabetes in China: Challenges and Actions

Paediatric type 2 diabetes in China—Pandemic, progression, and potential solutions

Understanding the standard of care in the treatment of type 2 diabetes in China: results from a national survey.

Type 1 diabetes mellitus care and education in China: The 3C study of coverage, cost, and care in Beijing and Shantou

PP93 Efficacy of Pharmacological Treatments for Type 2 Diabetes in China

China—leading the Way in Diabetes Research

Glycemic Control Rate of T2DM Outpatients in China: A Multi-Center Survey

Management Status of Type 2 Diabetes Mellitus in Tertiary Hospitals in Beijing: Gap Between Guideline and Reality.

Observational Study Evaluating the Effectiveness of Physician-Targeted Education for Improving Glycemic Management of Patients with Type 2 Diabetes (BEYOND II)

Chinese Childrens’ Diabetes Status, Trends and Hardship

Status of Blood Glucose Control and Treatment of Type 2 Diabetes in China

The Risk Factors of Glycemic Control, Blood Pressure Control, Lipid Control in Chinese Patients with Newly Diagnosed Type 2 Diabetes _ A Nationwide Prospective Cohort Study.

Evaluation of Effectiveness of Treatment Paradigm for Newly Diagnosed Type 2 Diabetes Patients in Chin: A Nationwide Prospective Cohort Study

China Diabetes Society 2016: A Call for Papers

Nationwide survey of physicians familiarity and awareness of diabetes guidelines in China: a cross-sectional study

Gaps of Medication Treatment Management Between Guidelines and Real-World for Inpatients With Type 2 Diabetes in China From Pharmacist's Perspective

Management of Chinese Patients with Type 2 Diabetes, 1998-2006: the Diabcare-China Surveys

Achievement of Guideline-Recommended Targets in Diabetes Care in China : A Nationwide Cross-Sectional Study.